Scribe Therapeutics Inc. Common Stock - Asset Resilience Ratio
Scribe Therapeutics Inc. Common Stock (SCTX) has an Asset Resilience Ratio of 45.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see Scribe Therapeutics Inc. Common Stock asset portfolio.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Scribe Therapeutics Inc. Common Stock's Asset Resilience Ratio has changed over time. Read debt load of Scribe Therapeutics Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Scribe Therapeutics Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See Scribe Therapeutics Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $29.35 Million | 45.01% |
| Total Liquid Assets | $29.35 Million | 45.01% |
Asset Resilience Insights
- Very High Liquidity: Scribe Therapeutics Inc. Common Stock maintains exceptional liquid asset reserves at 45.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Scribe Therapeutics Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Scribe Therapeutics Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.81% |
Annual Asset Resilience Ratio for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Scribe Therapeutics Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.74% | $45.17 Million | $78.22 Million | -14.59pp |
| 2024-12-31 | 72.34% | $92.57 Million | $127.97 Million | -- |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more